All-cause mortality due to conduction abnormalities in the United States: sex, racial, and geographic variations from 1999 to 2022.

Background: Mortality related to conduction abnormalities in the US population is not well-documented. Population-based stratification approaches can improve public health policies and targeted strategies.

Objective: To evaluate all-cause mortality related to conduction abnormalities in the US population METHODS: The CDC WONDER database was utilized to calculate the Age-Adjusted Mortality Rate (AAMR) per 100,000 individuals above 35 years old related to conduction abnormalities between 1999 and 2022.

Results: A total of 207,861 deaths were attributed to conduction abnormalities throughout the study period with 56,186 of these deaths occurring between 2020 and 2022. All-cause mortality related to conduction abnormalities has increased during the past decade with an exponential growth in 2020-2021 (COVID-19 era; Annual Percent Change (APC) of 16.6% per year). Although the mortality rates decreased in 2022, they remained elevated compared to 2019-2020. Throughout the past two decades, males consistently exhibited higher mortality rates than females, with the rate in 2022 being 1.5 times higher (AAMR 11.4 vs 7.0 per 100,000). Non-Hispanic Black patients experienced a significantly higher mortality rate compared to non-Hispanic White individuals in the study period (AAMR 13.7 vs. 8.6 per 100,000 in 2022). In the past two decades, mortality has been persistently higher in rural and small-medium-sized metro areas than in large metro urban areas.

Conclusions: Mortality rates related to conduction abnormalities have increased over the past decade, and persistent disparities have been observed. These data suggest that continued innovative outreach approaches and engagement with under-represented populations remain essential.